Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics

被引:76
作者
Mizuno, Tomoyuki [1 ]
Fukudo, Masahide [1 ]
Terada, Tomohiro [1 ]
Kamba, Tomomi [2 ]
Nakamura, Eijiro [2 ]
Ogawa, Osamu [2 ]
Inui, Ken-ichi [1 ]
Katsura, Toshiya [1 ]
机构
[1] Kyoto Univ Hosp, Dept Pharm, Kyoto 606, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan
关键词
ABCG2; ABCB1; transporter; pharmacogenetics; pharmacogenomics; tyrosine kinase inhibitor; RENAL-CELL CARCINOMA; SINGLE-NUCLEOTIDE POLYMORPHISMS; P-GLYCOPROTEIN; MDR1; GENE; TRANSPLANT RECIPIENTS; C3435T POLYMORPHISM; INTERFERON-ALPHA; PHASE-I; ABCG2; EXPRESSION;
D O I
10.2133/dmpk.DMPK-12-RG-026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To elucidate the impact of genetic variations in breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (MDR1/ABCB1) on the pharmacokinetics of sunitinib, we carried out a pharmacogenetic study in a clinical setting and pharmacokinetic analysis using Abcg2(-/-), Abcbla/1b(-/-) and Abcbla/1b;Abcg2-/- mice. Nineteen renal cell carcinoma patients were enrolled in this study. The plasma concentrations of sunitinib and its active metabolite were determined and the area under the concentration-time curve (AUC) was calculated. Genetic polymorphisms in ABCG2 (421C>A) and ABCBI (1236C>T, 2677G>T/A and 3435C>T) were examined. The dose-adjusted AUC(0-24) of sunitinib was significantly higher in patients with a heterozygous variant for ABCG2 421C>A than in wild-type patients (p = 0.02), and one homozygous patient showed the highest dose-adjusted AUC(0-24). The ABCB1 polymorphisms were not associated with the dose-adjusted AUC(0-24). The maximum concentration and AUC(0-4) of sunitinib were significantly higher in Abcg2(-/-), Abcbla/1b(-/-) and Abcbla/1b;Abcg2(-/-) mice than wild-type mice when sunitinib was given orally but not intraperitoneally. Incidence of thrombocytopenia and hypertension and poor compliance were associated with the systemic exposure to sunitinib and its active metabolite. These results suggest that the loss of protein expression of ABCG2 by genetic polymorphism is associated with an increase in the systemic exposure to sunitinib and sunitinib-induced toxicity.
引用
收藏
页码:631 / 639
页数:9
相关论文
共 42 条
[1]  
Aghazadeh-Habashi A, 2002, J PHARM PHARM SCI, V5, P181
[2]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[3]   The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients [J].
Breedveld, P ;
Pluim, D ;
Cipriani, G ;
Wielinga, P ;
van Tellingen, O ;
Schinkel, AH ;
Schellens, JHM .
CANCER RESEARCH, 2005, 65 (07) :2577-2582
[4]   A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period [J].
Britten, Carolyn D. ;
Kabbinavar, Fairooz ;
Hecht, J. Randolph ;
Bello, Carlo L. ;
Li, Jim ;
Baum, Charles ;
Slamon, Dennis .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) :515-524
[5]   Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [J].
Cascorbi, I ;
Gerloff, T ;
Johne, A ;
Meisel, C ;
Hoffmeyer, S ;
Schwab, M ;
Schaeffeler, E ;
Eichelbaum, M ;
Brinkmann, U ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :169-174
[6]   Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs [J].
Cascorbi, Ingolf .
PHARMACOLOGY & THERAPEUTICS, 2006, 112 (02) :457-473
[7]   Sunitinib: From rational design to clinical efficacy [J].
Chow, Laura Q. M. ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :884-896
[8]   Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression [J].
Chowbay, B ;
Li, HH ;
David, M ;
Cheung, YB ;
Lee, EJD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (02) :159-171
[9]   ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition [J].
de Jong, FA ;
Marsh, S ;
Mathijssen, RHJ ;
King, C ;
Verweij, J ;
Sparreboom, A ;
McLeod, HL .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5889-5894
[10]   Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study [J].
Garcia-Donas, Jesus ;
Esteban, Emilio ;
Javier Leandro-Garcia, Luis ;
Castellano, Daniel E. ;
Gonzalez del Alba, Aranzazu ;
Angel Climent, Miguel ;
Angel Arranz, Jose ;
Gallardo, Enrique ;
Puente, Javier ;
Bellmunt, Joaquim ;
Mellado, Begona ;
Martinez, Esther ;
Moreno, Fernando ;
Font, Albert ;
Robledo, Mercedes ;
Rodriguez-Antona, Cristina .
LANCET ONCOLOGY, 2011, 12 (12) :1143-1150